Home | EndoTODAY | EndoATLAS


[¼ÒÈ­±âº´¸®¿¬±¸È¸ Áý´ãȸ]

2014³â 6¿ù 19ÀÏ »ï¼º¼­¿ïº´¿ø º´¸®°ú ȸÀǽǿ¡¼­ '¼ÒÈ­±âº´¸®¿¬±¸È¸ Áý´ãȸ'°¡ ÀÖ¾ú½À´Ï´Ù. »ï¼º¼­¿ïº´¿ø ¼ÒÈ­±â³»°ú ¹Îº´ÈÆ ±³¼ö²²¼­ 'longterm outcome of endoscopic resection for EGC: clinicopathologic factors associated with recurrence and extragastric metastasis'¶ó´Â Á¦¸ñÀÇ Æ¯°­À» Çϼ̽À´Ï´Ù.

¹Îº´ÈÆ ±³¼ö´ÔÀº 2011³â±îÁö ³»½Ã°æ Ä¡·á¸¦ ÇÑ 2,036¸íÀ» 3³â ÀÌ»ó °æ°ú°üÂûÇÑ ÀڷḦ º¸¿©Áּ̽À´Ï´Ù. À̹ø ºÐ¼®¿¡¼­ 12°³¿ù À̳»¿¡ ¹ß°ßµÈ Ä¡·áºÎ ¾ÏÀº residual tumor·Î Á¤ÀÇÇÏ¿´½À´Ï´Ù.

Æò±Õ 48 °³¿ù ÃßÀû°üÂû±â°£ µ¿¾È extragastric recurrence 2¸íÀÌ ÀÖ¾ú½À´Ï´Ù. Absolute indicationÀ̾ú´ø 1¿¹´Â 63°³¿ù¿¡, expanded indicationÀ̾ú´ø 1¿¹´Â 49°³¿ù¿¡ extragastric recurrence°¡ ¹ß°ßµÇ¾ú½À´Ï´Ù. º» º´¿ø Áõ·Ê¸¦ Æ÷ÇÔÇÏ¿© Áö±Ý±îÁö ¹®Çå¿¡ º¸°íµÈ extragastric recurrence´Â 8¿¹(mortality 3¿¹ Æ÷ÇÔ)¶ó°í ÇÕ´Ï´Ù.

Metachronous recurrence´Â 5³â µ¿¾È linearÇÏ°Ô ¹ß°ßµÇ¾ú°í, 5³â ÀÌÈÄ¿¡´Â ¾à°£ °¨¼ÒµÇ´Â °æÇâÀ̾ú½À´Ï´Ù. ¹Î±³¼ö´ÔÀº metachronous recurrence°¡ ½ÇÁ¦·Î ÁÙ¾îµå´Â °ÍÀÎÁö ¾Æ´Ï¸é 5³â ÀÌÈÄ¿¡´Â °Ë»ç¸¦ ´úÇϱ⠶§¹®¿¡ ´ú ¹ß°ßµÇ´Â °ÍÀÎÁö ¸íÈ®ÇÏÁö ¾Ê´Ù´Â ÀÇ°ßÀ» Áּ̽À´Ï´Ù. ¹Îº´ÈÆ ±³¼ö´Ô¿¡ ÀÇÇϸé Metachronous recurrence´Â microsatellite recurrence¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Cancer stem cell-related surface markerÀÎ CD44 variant 9 ¾ç¼º¿¹¿¡¼­metachronous recurrence°¡ ¸¹´Ù´Â ÀϺ» º¸°íµµ ¼Ò°³Çϼ̽À´Ï´Ù.

ESD ÈÄ 10.7%Á¤µµ¿¡¼­ ¹ß°ßµÇ´Â mixed type¿¡¼­ ¼ö¼ú¿©ºÎ °áÁ¤Àº ¾î·Æ½À´Ï´Ù. Mixed typeÀÇ °æ¿ì ÀϺ»¿¡¼­´Â (1) Á¡¸·¾ÏÀÌ°í 3.0 cm ¹Ì¸¸ÀÌ¶óµµ ulcer°¡ ÀÖÀ¸¸é, (2) undifferentiated area°¡ 2.0 cm ÀÌ»óÀ̸é, (3) SM invasion ºÎÀ§°¡ undifferentiated typeÀÎ °æ¿ì(Hanaoka ¿¬±¸ÀÇ invasion front¿Í ºñ½ÁÇÑ °³³ä °°À½)´Â ¼ö¼úÀ» ±ÇÇÑ´Ù°í ÇÕ´Ï´Ù. ¾ÆÁ÷Àº Á¶½ÉÇÏ´Â ºÐÀ§±â °°½À´Ï´Ù.

WHYXÀÇ º´¸®Áø´Ü¿¡ ´ëÇؼ­ º´¸®°ú ¼±»ý´Ôµé »çÀÌ¿¡¼­ ±ä Åä·ÐÀÌ ÀÖ¾ú½À´Ï´Ù. º´¸® Áø´Ü°ú ¿ë¾î´ëÇÑ ÀÇ°ßÀÌ ¾ÆÁ÷ ÅëÀϵÇÁö ¸øÇØ º¸¿´½À´Ï´Ù. È°¹ßÇÏ°Ô ¿¬±¸µÇ°í ÀÖ´Â ¿µ¿ª°°½À´Ï´Ù. ÃÖ±Ù ÀϺ»ÀÇ ¿¬±¸¿¡ ÀÇÇϸé Very well-differentiated gastric carcinoma of intestinal type (¾Æ¸¶µµ WHYX¿Í ºñ½ÁÇÑ ÇüÅÂ)ÀÇ Àý¹Ý Á¤µµ´Â Á¶Á÷°Ë»ç·Î Áø´ÜÇÒ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÌ¿¡ ´ëÇÏ¿© ¿ì¸®³ª¶ó º´¸®ÀÇ»çµéÀº ¹Ý½Å¹ÝÀÇÇÏ´Â ºÐÀ§±â¿´½À´Ï´Ù.